Entity > Corporation > US > New York City New York > Inhibrx

About Inhibrx

Inhibrx, Inc. is a clinical-stage biotechnology company dedicated to helping people with life-threatening diseases through scientific innovation and excellence. Inhibrx, Inc. employs various protein engineering methods to address the specific needs of complex targets and diseases, including its proprietary sdAb platform.

The Proprietary Sdab Platform From Inhibrx, Inc: Our proprietary sdAb platform enables us to address complex target biology where other biological approaches have failed or are suboptimal. Our precision engineering enables the generation of therapeutic candidates with defined valences and specificities that we believe can lead to optimal mechanisms of action.

Currently, Four Inhibrx, Inc. Programs Are In Ongoing Clinical Trials: Drawing on the breadth and depth of our team's experience and capabilities, and using our proprietary technology, we have developed a promising pipeline that we believe has properties and mechanisms of action superior to existing approaches in the field. Three programs target the treatment of various cancers and one targets alpha-1 antitrypsin deficiency (AATD). In addition, INBRX-121 is our newest preclinical program currently in cell line development.

Inhibrx, Inc. And Bluebird Bio Began A Research Collaboration In 2016: Since then, the collaboration has focused on the discovery, development and commercialization of chimeric antigen receptor (CAR) T-cell therapies using Inhibrx's proprietary single-domain antibody (sdAb) platform for multiple cancer targets.

The Formation And Headquarters Of Inhibrx, Inc: Inhibrx was founded in 2010 and is currently headquartered in La Jolla, California, USA.

The Mission Of Inhibrx, Inc. Is To Provide Optimized Biologic Therapeutics To People With Life-Threatening Diseases: To achieve this goal, we have built a large and diverse pipeline that has the potential to impact cancer and rare diseases through our single-domain antibody platform technology. Single-domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in multiple ways to meet the specific needs of unique biological targets.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Inhibrx